Matching Breast Cancer Patients to Therapies: Here’s How

Oncology News Central Peer-Spectives

The landscape for breast cancer treatment is shifting quickly, with an ever-increasingemphasis on targeted and hormonal therapies. Listen as Virginia Kaklamani,MD, professor of medicine in the division of hematology oncology at UT Health San Antonio, and medical directorof the breast oncologyprogram at UT Health San Antonio, MD Anderson Cancer Center,talks with Bob Figlin, MD, Steven Spielberg Family Chair in Hematology-OncologyatCedars-Sinai Cancer,about key findings coming out of the 2022 San Antonio Breast Cancer Symposium. She shares how she’ll use elacestrant following updated results from the EMERALD trial, how to select patients for ovarian suppression, and the expanding role of CDK4/6 inhibitors. “[T]here's no role for combination chemotherapy in first-line [estrogen receptor]-positive metastatic breast cancer anymore –even in patients that are deemed to have visceral crisis,”she said.